Author (Year) | Trial Name | Study Phase | Phase Treatment | Regimen | No. Patients | Median Age (Years) | Median Duration of Treatment (Months) |
---|---|---|---|---|---|---|---|
Niesvizky (2015) [14] | UPFRONT | 3 | ND | Bortezomib/dexamethasone | 165 | 74.5 | 6 |
 |  |  |  | Bortezomib/thalidomide/dexamethasone | 158 | 73 | 4.6 |
 |  |  |  | Bortezomib/melphalan/prednisone | 163 | 72 | 4.7 |
Richardson (2015) [33] | Â | 2 | RR | Elotuzumab/lenalidomide/dexamethasone | 73 | 62 | 19.1 |
Mateos (2019) [15] | ALCYONE | 3 | ND | Daratumumab/bortezomib/melphalan/prednisone | 346 | 71 | 13.5 |
Voorhees (2019) [16] | GRIFFIN | 2 | ND | Daratumumab/lenalidomide/bortezomib/dexamethasone | 99 | 59 | 22.1 |
Usmani (2019) [38] | KEYNOTE-185 | 3 | RR | Pembrolizumab/lenalidomide/dexamethasone | 149 | 74 | 4.4 |
Mateos (2019) [40] | COLUMBA | 3 | RR | Subcutaneous daratumumab | 260 | 65 | 7.5 |
 |  |  |  | IV daratumumab | 258 | 68 | 7.5 |
Spicka (2019) [34] | ADMYRE | 3 | RR | Plitidepsin/dexamethasone | 167 | 64 | 3 |
Rosinol (2019) [17] | PETHEMA/GEM2012 | 3 | ND | Bortezomib/lenalidomide/dexamethasone prior to transplant | 458 | 58 | 6 |
Attal (2019) [35] | ICARIA-MM | 3 | RR | Isatuximab/pomalidomide/dexamethasone | 152 | 68 | 10.2 |
Morgan (2019) [41] | TOURMALINE-MM3 study | 3 | M | Ixazomib maintenance | 395 | 58 | 15.2 |
Moreau (2019) [36] | BELLINI | 3 | RR | Venetoclax/bortezomib/dexamethasone | 194 | 66 | 18.7 |
Moreau (2019) [18] | CASSIOPEIA | 3 | ND | Daratumumab/bortezomib/melphalan/prednisone prior to and following transplant | 536 | 59 | 8.9 |
Richardson (2019) [27] | OPTISIMISMM | 3 | RR | Bortezomib/pomalidomide/dexamethasone | 278 | 67 | 8.8 |
Mateos (2019) [26] | KEYNOTE-183 | 3 | RR | Pembrolizumab/pomalidomide/dexamethasone | 120 | 65 | 4.1 |
Dimopoulos (2018) [30] | POLLUX | 3 | RR | Daratumumab/lenalidomide/dexamethasone | 283 | 65 | 24.5 |
Jackson (2019) [24] | Myeloma XI | 3 | ND | Cyclophosphamide/bortezomib/dexamethasone induction | 275 | 66 | 2.8 |
Horvath (2019) [19] | VCAT | 3 | ND | Bortezomib/thalidomide/prednisolone consolidation | 103 | 58 | 10.2 |
Facon (2019) [23] | CLARION | 3 | ND | Carfilzomib/melphalan/prednisone | 474 | 72 | 13.1 |
Facon (2019) [20] | MAIA | 3 | ND | Daratumumab/lenalidomide/dexamethasone | 364 | 73 | 25.3 |
Lonial (2015) [25] | ELOQUENT-2 | 3 | RR | Elotuzumab/lenalidomide/dexamethasone | 318 | 67 | 17 |
Dimopoulos (2016) [37] | ENDEAVOR | 3 | RR | Carfilzomib | 463 | 65 | 10 |
Spencer (2018) [31] | CASTOR | 3 | RR | Daratumumab/bortezomib/dexamethasone | 243 | 64 | 13.4 |
Moreau (2018) [28] | A.R.R.O.W. | 3 | RR | Once weekly carfilzomib | 238 | 66 | 9.5 |
 |  |  |  | Twice weekly carfilzomib | 235 | 66 | 7.3 |
Dimopoulos (2018) [29] | ELOQUENT-3 | 2 | RR | Elotuzumab/pomalidomide/dexamethasone | 60 | 69 | 8.4 |
Hajek (2016) [32] | FOCUS | 3 | RR | Carfilzomib | 157 | 63 | 4.1 |
Durie (2017) [21] | SWOG S0777 | 3 | ND | Bortezomib/lenalidomide/dexamethasone non-transplant | 242 | 63 | 5.6 |
Bringhen (2019) [42] | EMN01 | 3 | M | Lenalidomide maintenance | 204 | 73 | 32.4 |
 |  |  |  | Lenalidomide/prednisone maintenance | 198 | 73 | 29.8 |
Zweegman (2016) [43] | HOVON-NSMG | 3 | M | Thalidomide maintenance | 121 | 72 | 5 |
 |  |  |  | Lenalidomide maintenance | 124 | 73 | 17 |
Moreau (2016) [39] | Â | 3 | RR | Ixazomib/lenalidomide/dexamethasone | 361 | 66 | 15.9 |
Jacobus (2016) [22] | E1A05 | 3 | NF | Bortezomib/lenalidomide/dexamethasone consolidation, | 23 | Â | 4.55 |
Gay (2015) [44] | Â | 3 | M | Lenalidomide maintenance | 117 | 57 | 28.9 |
 |  |  |  | lenalidomide/prednisone maintenance | 106 | 56 | 25.3 |